GlassScriptPhysician profile
Margaret S Brady
NPI 1356721096
$9,125.63
in general payments reported to CMS, 2019-2025
68 companies · $2,930 in 2025
The $2,930 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.21 · 2020: $298 · 2021: $250 · 2022: $1,079 · 2023: $1,916 · 2024: $2,602 · 2025: $2,930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,106 · Education: $342.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,105.72 |
| Education | $342.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $726.30 | 2021-2025 | |
| Janssen Biotech, INC. | $635.12 | 2021-2025 | Erleada, Rybrevant, Darzalex |
| Merck Sharp & Dohme LLC | $602.64 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $563.57 | 2020-2025 | Enhertu, Injectafer, Datroway |
| Gilead Sciences, INC. | $402.54 | 2022-2025 | Trodelvy |
| Amgen INC. | $392.64 | 2020-2023 | Lumakras, Kyprolis, Blincyto |
| Lilly USA, LLC | $360.68 | 2022-2025 | Verzenio, Jaypirca, Retevmo |
| Incyte Corporation | $353.94 | 2023-2025 | Jakafi, Monjuvi, Pemazyre |
| Pfizer INC. | $351.18 | 2022-2025 | |
| Abbvie INC. | $300.68 | 2022-2025 | Venclexta |
| Astrazeneca Pharmaceuticals LP | $281.44 | 2023-2025 | Calquence, Enhertu, Tagrisso |
| E.R. Squibb & Sons, L.L.C. | $237.65 | 2022-2025 | Opdivo, Eliquis, Krazati |
| Celgene Corporation | $236.38 | 2022-2025 | Reblozyl, Pomalyst |
| Genzyme Corporation | $232.97 | 2021-2025 | |
| Deciphera Pharmaceuticals INC. | $196.04 | 2023-2025 | Qinlock, Romvimza |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $193.87 | 2022-2025 | Ninlaro, Hyqvia, Alunbrig |
| Genentech USA, INC. | $189.20 | 2023-2025 | Venclexta, Tecentriq, Phesgo |
| Glaxosmithkline, LLC. | $182.85 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Regeneron Healthcare Solutions, INC. | $160.28 | 2021-2025 | Libtayo |
| Sobi, INC | $156.79 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $131.97 | 2024-2025 | |
| Taiho Oncology, INC. | $125.72 | 2024-2025 | |
| Rigel Pharmaceuticals, INC. | $118.95 | 2023-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Bayer Healthcare Pharmaceuticals INC. | $116.36 | 2023-2025 | |
| Pharmaessentia USA Corporation | $107.40 | 2024-2025 | Besremi |
| Stemline Therapeutics INC. | $106.65 | 2024-2025 | Orserdu |
| Eisai INC. | $80.85 | 2022-2024 | |
| Adaptive Biotechnologies Corporation | $77.97 | 2024-2025 | Clonoseq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.53 | 2024-2025 | |
| Array Biopharma INC | $69.18 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Mirati Therapeutics, INC. | $68.72 | 2023 | Krazati |
| Seagen INC. | $67.55 | 2022-2023 | Adcetris, Tukysa |
| Beigene USA, INC. | $66.12 | 2023-2025 | Brukinsa |
| Astellas Pharma US INC | $62.70 | 2023-2024 | Padcev |
| Alexion Pharmaceuticals, INC. | $61.73 | 2024-2025 | Ultomiris |
| Secura Bio, INC. | $56.24 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $55.33 | 2024-2025 | Onivyde, Somatuline Depot |
| Tersera Therapeutics LLC | $52.88 | 2022-2025 | Zoladex |
| Fresenius Kabi USA, LLC | $52.27 | 2025 | Stimufend |
| Genentech, INC. | $52.21 | 2019 | |
| Puma Biotechnology, INC. | $50.16 | 2023-2025 | |
| Alnylam Pharmaceuticals INC. | $47.86 | 2024-2025 | Givlaari |
| Shield Therapeutics INC | $43.90 | 2024-2025 | |
| Adc Therapeutics America, INC. | $39.38 | 2025 | |
| Karyopharm Therapeutics INC. | $39.17 | 2022-2023 | Xpovio |
| Pharmacosmos Therapeutics INC. | $37.15 | 2022-2024 | Cosela |
| Servier Pharmaceuticals LLC | $36.57 | 2023-2025 | |
| Iovance Biotherapeutics, INC. | $31.38 | 2025 | Amtagvi |
| Dendreon Pharmaceuticals LLC | $29.92 | 2025 | Provenge |
| Morphosys, US INC. | $29.13 | 2022-2023 | Monjuvi |
| Emd Serono, INC. | $28.72 | 2023-2024 | Bavencio |
| Menarini Silicon Biosystems, INC. | $28.15 | 2023 | Cellsearch |
| Emmaus Medical, INC. | $27.91 | 2022 | |
| Tempus Ai, INC | $27.05 | 2024 | Xt Cdx |
| Aveo Pharmaceuticals, INC. | $26.14 | 2024 | |
| Geron Corporation | $25.58 | 2025 | Rytelo |
| Acrotech Biopharma INC. | $25.10 | 2024 | Beleodaq |
| Beone Medicines USA, INC. | $22.98 | 2025 | Tevimbra |
| Blue Earth Diagnostics | $22.58 | 2022 | |
| Cti Biopharma Corp. | $19.43 | 2022 | |
| Agios Pharmaceuticals, INC. | $19.25 | 2024 | Pyrukynd |
| Recordati_rare_diseases_inc. | $18.87 | 2025 | Sylvant |
| Kyowa Kirin, INC. | $17.32 | 2025 | |
| G1 Therapeutics, INC. | $16.76 | 2023 | Cosela |
| Cumberland Pharmaceuticals, INC. | $14.44 | 2023 | Sancuso |
| Sumitomo Pharma America, INC. | $13.69 | 2024 | Orgovyx |
| Medtronic, INC. | $12.79 | 2023 | Osteocool Rf Ablation System |
| Myovant Sciences INC. | $12.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Brady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.